LawrenceGarboMD

Oncology • Albany, NY

Physician

Join to view full profile

Dr. Garbo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garbo's full profile

Already have an account?

Office
400 Patroon Creek Blvd
Suite 1
Albany, NY 12206
Phone+1 518-489-0044

Fax+1 518-489-3591

Education & Training

Albany Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1983
Albany Medical CenterResidency, Internal Medicine, 1977 - 1980
University of Vermont College of MedicineClass of 1977

Certifications & Licensure

NY State Medical License 1980 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell Start of enrollment: 2004 Dec 01
Completed
Phase 2
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

32 citations
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
Costantine Albany, Lawrence H. Einhorn, Lawrence Garbo, Thomas E. Boyd, Neil C Josephson
The Oncologist. 2018-03-01
39 citations
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Guru Sonpavde, Ana Aparicio, Feng Zhan, Brittany North, Robert Delaune
Urologic Oncology. 2011-11-01
11 citations
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluor...
Tracy Murray Stewart, Daniel D. Von Hoff, Michael L. Fitzgerald, Laurence J. Marton, Carlos Becerra
Cancer Chemotherapy and Pharmacology. 2021-01-01